Skip to main content
BTSGBrightSpring Health Services, ISell5.5·$68.40
BTSG · Decision

Should you buy BrightSpring Health Services, I (BTSG)?

Updated

The company delivers 26% year-over-year revenue growth with exceptional cash conversion and a consistent earnings beat track record, but the stock has already surpassed its price target and trades within 0.2% of its 52-week high — the reward-to-risk ratio has turned unfavorable and the setup favors trimming rather than adding.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Verdict
SELL
Score
5.5/10
Price
$68.40
Entry / Take Profit (TP) / Stop Loss (SL)
/ $67.73 / $64.27

Engine methodology range

Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.

What the engine is tracking

Revenue is expanding at 26% year-over-year and the company has beaten earnings estimates in three of the last four quarters with an average positive surprise of roughly 13%, demonstrating that operational execution is consistently running ahead of expectations.

Stable
Growth breakdown
Expectation
Revenue growth sustains above 20% year-over-year and the earnings beat streak extends to at least 4 of the next 5 quarters, reinforcing the execution narrative.

CounterHigh headline growth may mask concentration risks — the risk notes flag two material items from annual-report disclosures — and if those concentrated exposures deteriorate, the growth rate could reverse quickly.

Free cash flow is running at 327% of net income, a ratio indicating the business generates substantially more cash than reported earnings imply — a genuine quality backstop beneath the growth story that reduces the risk of an earnings-quality surprise.

Stable
Quality breakdown
Expectation
Free cash flow to net income ratio remains above 150% over the next four quarters, confirming the cash generation is structural rather than a one-period anomaly.

CounterAn FCF-to-net-income ratio far above 100% can reflect accounting differences such as non-cash charges inflating cash flow; without a competitive moat to protect margins, this conversion rate may not persist through a business cycle.

The current price has moved above the price target, leaving negative headroom to the upside level — the stock has already realized the anticipated move, and the reward-to-risk ratio has turned unfavorable with more downside than upside at this entry.

Stable
Price targets
Expectation
This pillar is falsified if the analyst consensus price target is revised upward such that upside from the current price exceeds 15%, re-establishing a positive risk/reward.

CounterStocks frequently trade through near-term price targets during strong momentum phases; the 26% growth trajectory and strong cash conversion could support a higher fundamental valuation than the current target captures.

▸ Show 1 more pillar

A leverage ratio that has triggered a penalty, no identifiable competitive moat, and a below-average quality score together raise the question of whether high growth is being funded in a way that limits long-term compounding power and increases downside risk if growth slows.

Stable
Bear case
Expectation
This pillar is falsified if the debt-to-equity ratio declines by more than 20% from current levels over four consecutive quarters while the quality score rises above 5.0.

CounterEarly-phase growth businesses often carry higher leverage as a deliberate choice to fund expansion; if the 26% growth rate justifies the borrowing cost, current leverage could reflect disciplined capital allocation rather than financial fragility.

→ Full pillar scorecard with all 4 pillars + per-dimension breakdown

When this thesis breaks

Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Revenue is expanding at 26% year-over-year and the company has beaten earnings estimates in three of the last four quarters with an average positive surprise of roughly 13%, demonstrating that operational execution is consistently running ahead of expectations.

    Trip ifRevenue growth falls below 15% YoY for 2 consecutive quarters.

  • P2Free cash flow is running at 327% of net income, a ratio indicating the business generates substantially more cash than reported earnings imply — a genuine quality backstop beneath the growth story that reduces the risk of an earnings-quality surprise.

    Trip ifFree cash flow to net income ratio falls below 100% for 2 consecutive quarters.

  • P3The current price has moved above the price target, leaving negative headroom to the upside level — the stock has already realized the anticipated move, and the reward-to-risk ratio has turned unfavorable with more downside than upside at this entry.

    Trip ifAnalyst consensus price target is revised upward such that upside from the current price exceeds 15%.

  • P4A leverage ratio that has triggered a penalty, no identifiable competitive moat, and a below-average quality score together raise the question of whether high growth is being funded in a way that limits long-term compounding power and increases downside risk if growth slows.

    Trip ifDebt-to-equity ratio declines by more than 20% from current levels over 4 consecutive quarters.

How the engine reached this verdict

1. Direct answer

TrendMatrix's engine output for BrightSpring Health Services, I (BTSG) is SELL_IF_HOLDING with medium conviction, score 5.5/10 at $68.40. The F-path SELL output reflects an overall score of 5.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -0.85 is supplementary context, not the trigger.

2. Entry, target, and stop

The engine's exit framework anchors to a tactical sell band near $68.40, with structural invalidation at $64.27. The asymmetric R:R against a reversal hypothesis is -0.15 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).

3. What the engine sees

On the bull side: Strong earnings beat streak (3/4); Strong growth profile; Recent Analyst Cluster(6) detected in news. On the bear side: Analyst target reached - limited upside remaining; Near 52-week high (1.1% away); Leverage penalty (D/E 1.4): -0.5. Active engine warnings: V8: Target reached (-12.7% upside), V9 Gate Failed: ASYMMETRY:-0.8=NEGATIVE.

4. What would change the verdict

The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.5>=5.5.

For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates BTSG — 10-dimension breakdown →

Bull case

  • Strong earnings beat streak (3/4)
  • Strong growth profile
  • Recent Analyst Cluster(6) detected in news

Bear case

  • Analyst target reached - limited upside remaining
  • Near 52-week high (1.1% away)
  • Leverage penalty (D/E 1.4): -0.5
Home Stocks BTSG Buy or sell?